Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Taper Plan Clear all
Not listed Not applicable Interventional

Impact of a Behavioral Tele-health Program on the Quality of Recovery for Patients Undergoing Total Joint Replacement Surgery

NCT05367050
View directory record Official record
Conditions
Opioid Dependence, Opioid Use, Pain, Joint
Interventions
Lucid Lane Therapy Program, Surgical Preparedness Course
Behavioral
Lead sponsor
Lucid Lane, Inc
Industry
Eligibility
21 Years to 90 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 13, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

NCT01790295
View directory record Official record
Conditions
Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis
Interventions
Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Westwood, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 13, 2026, 6:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Smoking Cessation in Women With Gynecological Conditions

NCT01989923
View directory record Official record
Conditions
Cervical Dysplasia
Interventions
Nicotine Replacement Therapy, Electronic Cigarettes
Other · Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 13, 2026, 6:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

NCT00241358
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Lymphocytic Leukemia, Chronic, Myelodysplastic Syndromes, Multiple Myeloma, Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions
AMD3100, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 13, 2026, 6:59 PM EDT
Completed No phase listed Observational

The Effect of Primary Care Opioid Taper Plans on Sustained Opioid Taper

NCT03748862
View directory record Official record
Conditions
Opiate Replacement Therapy
Interventions
Taper Plan
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 13, 2026, 6:59 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The PRIME Study: A Randomized, Controlled, Prospective Study

NCT04549935
View directory record Official record
Conditions
Patient Preference, Patient Outcomes, Post-Operative Inflammation, Grade of Post-Operative Cystoid Macular Edema, Rate of Post-Operative Cystoid Macular Edema
Interventions
Dextenza, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision - MT
Other
Eligibility
22 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 13, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Results available

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

NCT03755414
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile
Procedure · Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 13, 2026, 6:59 PM EDT
Recruiting Not applicable Interventional

Opioid Tapering After Hospital Discharge: Testing an Intervention to Improve Post-operative Opioid Prescribing

NCT07510373
View directory record Official record
Conditions
Opioid Tapering
Interventions
Treatment as Usual (TAU), Telephonic Support (TS) Providers, DOTS Intervention
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 13, 2026, 6:59 PM EDT
Not listed Not applicable Interventional

Collaborative Opioid Taper After Trauma: Preventing Opioid Misuse and Opioid Use Disorder

NCT04275258
View directory record Official record
Conditions
Opioid Use, Pain, Postoperative, Opioid Use, Unspecified, Trauma, Opioid-use Disorder
Interventions
Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 13, 2026, 6:59 PM EDT
Completed Not applicable Interventional Results available

Effect of Personalized Pain Coaches After Orthopaedic Surgery for Patients With Sports Medicine Injuries

NCT05821699
View directory record Official record
Conditions
Sports Medicine Injuries
Interventions
LCS (Life Care Specialist), Standard of Care
Behavioral
Lead sponsor
Emory University
Other
Eligibility
15 Years to 45 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 13, 2026, 6:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

NCT01875237
View directory record Official record
Conditions
Leukemia, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 13, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Pediatric GVHD Low Risk Steroid Taper Trial

NCT05090384
View directory record Official record
Conditions
Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
Interventions
Prednisone
Drug
Lead sponsor
John Levine
Other
Eligibility
Up to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 13, 2026, 6:59 PM EDT
Completed Not applicable Interventional

Impact of Daily, Digital and Behavioral Tele-health Tapering Program for Perioperative Surgical Patients Exposed to Opioids and Benzodiazepines.

NCT04787692
View directory record Official record
Conditions
Elective Spine Surgery Receiving Pre and/or Postoperative Pain Control With Opioids
Interventions
Opioid and Benzodiazepine Naive-patients, Opioid and Benzodiazepine Tolerant-patients
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 13, 2026, 6:59 PM EDT
Completed Not applicable Interventional

SWEET: Postpartum Navigation After GDM

NCT04583839
View directory record Official record
Conditions
Gestational Diabetes, Preventive Care / Anticipatory Guidance, Retention in Care, Postpartum Health, Lifestyle Modification
Interventions
Patient Navigation Program
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 13, 2026, 6:59 PM EDT
Recruiting Phase 1 Interventional

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

NCT07302776
View directory record Official record
Conditions
GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis (MF), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Tacrolimus, Early Tacrolimus Taper Strategy
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 13, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Treat Major Depressive Disorder (MDD) With a New Medication

NCT02149836
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
ezogabine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 13, 2026, 6:59 PM EDT
Active, not recruiting Phase 2 Interventional

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

NCT04904588
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Interventions
Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes
Drug · Radiation · Procedure + 1 more
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
1 Year and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
39
States / cities
Duarte, California • San Francisco, California • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 13, 2026, 6:59 PM EDT
Recruiting Not applicable Interventional

Preoperative Opioid Tapering Before Spine Surgery

NCT07221786
View directory record Official record
Conditions
Opioid Consumption, Postoperative, Pain After Surgery, Opioid Dependency
Interventions
Opioid tapering with CBT and education, Opioid tapering with education alone
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadephia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 13, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT00720629
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Visilizumab, Tacrolimus, Methotrexate, Antithymocyte globulin (ATG)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 13, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease

NCT03483675
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Immunosuppressive Therapy, Survey Administration
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 13, 2026, 6:59 PM EDT
Active, not recruiting Phase 2 Interventional

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04329325
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive
Interventions
Blinatumomab, dasatinib, dexamethasone, methotrexate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 13, 2026, 6:59 PM EDT
Recruiting Not applicable Interventional

Time-restricted Eating for Postpartum Weight Loss

NCT06491537
View directory record Official record
Conditions
Postpartum Weight Retention, Overweight and Obesity
Interventions
Early Time-Restricted Eating (eTRE), Control
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 13, 2026, 6:59 PM EDT
Terminated Not applicable Interventional

OCT-guided LALAK in Children

NCT01579643
View directory record Official record
Conditions
Corneal Opacity
Interventions
OCT guided laser-assisted lamellar anterior keratoplasty (LALAK), Penetrating Keratoplasty (KP)
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Month to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 13, 2026, 6:59 PM EDT
Completed Not applicable Interventional Results available

Cognitive Behavioral Therapy and Chronic Pain Self-Management Within the Context of Opioid Reduction: The EMPOWER Study

NCT03445988
View directory record Official record
Conditions
Chronic Pain
Interventions
Cognitive Behavioral Therapy, Chronic Pain Self Management Program, Taper Only
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 13, 2026, 6:59 PM EDT